| VRTX |
Report |
Total revenue (Q2'26) |
BEAT |
pred ~$3.28B vs. cons $3.23B |
MEDIUM |
| VRTX |
Report |
Non-GAAP EPS (Q2'26) |
BEAT |
pred ~$5.00 vs. cons $4.85 |
MEDIUM |
| VRTX |
Report |
JOURNAVX (suzetrigine) revenue |
MISS |
pred ~$48M vs. cons ~$62M |
LOW |
| VRTX |
Guide |
FY26 total revenue guide |
UNCHANGED |
guide ~$12.95-13.1B vs. cons ~$13.0B (FY26, ex-Crinetics until Q3 close) |
MEDIUM |
| VRTX |
Guide |
FY26 non-GAAP EPS (Crinetics dilution) |
LOWER |
guide ~$16.4 vs. cons ~$17.01 (FY26, once Crinetics folds in) |
LOW |
| VRTX |
Guide |
FY26 non-CF product revenue target |
UNCHANGED |
guide ~$500M+ vs. cons ~$500M (FY26) |
MEDIUM |
| VRTX |
Guide |
FY26 combined non-GAAP OpEx |
UNCHANGED |
guide ~$5.65-5.75B vs. cons ~$5.70B (FY26, pre-deal) |
MEDIUM |
| VRTX |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.5% |
— |
LOW |
| VRTX |
Return |
5-day cumulative residual |
-3.5% (FOLLOW-THROUGH) |
Headline is a modest beat/reiterate that's largely priced in a range-bound, low-beta (~0.19) name, so the reaction hinges on the JOURNAVX revenue-vs-script gap and Crinetics dilution overhang. A soft JOURNAVX print keeps the 'show-me' H2 inflection unproven and pressures out-period pain-franchise estimates, while Crinetics (accretive only in 2029) drags FY EPS revisions lower — implicit cuts pull estimates down even after a top-line beat, so an initial dip should modestly follow through rather than reverse. CF durability limits the downside but isn't enough to spark a rebound. |
LOW |